Regulatory FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) Big Molecule WatchOn April 2, 2026, Regeneron Pharmaceuticals announced that the U.S.RegulatoryOphthalmologyRead full story pharminent April 15, 2026 Big Molecule Watch On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S. RegulatoryOphthalmologyRead full story Post navigation Previous: Lilly to acquire CrossBridge Bio for up to $300mNext: Travere wins long-awaited approval for kidney disease drug Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
